NAD-capped RNA transcriptomes in healthy populations
Conditions
Interventions
Middle-aged and elderly treatment group:Oral NMN150mg/day
Middle-aged and elderly control group:Oral placebo 150mg/day
Sponsors
Changzheng Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. BMI between 18.5-25kg/m2, stable weight (±2 kg) in the past 3 months. 2. Sign the informed consent. 3. There are no significant abnormalities in physical examination and auxiliary examination parameters before enrollment, no serious diseases such as heart, liver and kidney, and women are not pregnant. 4. Able to follow oral and written research protocols, participate in 2-month trial follow-up, and provide blood samples. 5. Have not taken any form of niacin supplements (including NR (nicotinamide riboside), NAM (nicotinamide), NA (niacin, vitamin B3)) within six months. 6. No symptoms related to niacin deficiency within half a year, that is, diseases characterized by dermatitis, glossitis, enteritis, mental disorders and peripheral neuritis.
Exclusion criteria
Exclusion criteria: 1. Taking any other individual form of niacin supplements (including NR (nicotinamide riboside), NAM (nicotinamide), NA (niacin, vitamin B3)) during the trial. 2. Newly diagnosed digestive system diseases or major diseases affecting the life expectancy of subjects during the trial. 3. Having personal events that may affect participants' compliance with protocol requirements, as assessed by the investigator. 4. Long-term drinking history, smoking history.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NAD-cappedRNA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events; | — |
Countries
China
Contacts
Public ContactLefeng Qu
Shanghai Changzheng Hospital
Outcome results
None listed